Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) - Pipeline Review, H1 2018

  • ID: 4576123
  • Report
  • 118 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • Arbor Pharmaceuticals LLC
  • Bayer AG
  • BioApex sro
  • Biogen Inc
  • Daiichi Sankyo Co Ltd
  • Evgen Pharma Plc
  • MORE
Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) - Pipeline Review, H1 2018

Summary:

Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) pipeline Target constitutes close to 37 molecules. Out of which approximately 27 molecules are developed by companies and remaining by the universities/institutes. The latest report Nuclear Factor Erythroid 2 Related Factor 2 - Pipeline Review, H1 2018, outlays comprehensive information on the Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) - Nuclear factor (erythroid-derived 2)-like 2 or Nrf2 is a transcription factor encoded by the NFE2L2 gene. It binds to antioxidant response elements in the promoter regions of target genes. It is important for the coordinated up-regulation of genes in response to oxidative stress. It is involved in the transcriptional activation of genes of the beta-globin cluster by mediating enhancer activity of hypersensitive site 2 of the beta-globin locus control region.

The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 4, 3, 4, 15 and 1 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 8 and 2 molecules, respectively. Report covers products from therapy areas Central Nervous System, Immunology, Oncology, Metabolic Disorders, Cardiovascular, Respiratory, Ophthalmology, Gastrointestinal, Genito Urinary System And Sex Hormones, Toxicology, Genetic Disorders, Infectious Disease and Musculoskeletal Disorders which include indications Inflammation, Multiple Sclerosis, Diabetic Nephropathy, Chronic Obstructive Pulmonary Disease (COPD), Friedreich Ataxia, Psoriasis, Type 2 Diabetes, Amyotrophic Lateral Sclerosis, Chronic Kidney Disease (Chronic Renal Failure), Mitochondrial Diseases, Parkinson's Disease, Pulmonary Arterial Hypertension, Retinal Degeneration, Systemic Sclerosis (Scleroderma), Type 1 Diabetes (Juvenile Diabetes), Age Related Macular Degeneration, AIDS Associated Dementia, Alport Syndrome, Alzheimer's Disease, Aspiration Pneumonitis, Asthma, Atherosclerosis, Autism, Brain Ischemia, Breast Cancer, Cardiomyopathy, Cardiovascular Disease, Cerebral Vasospasm, Chagas Disease (American Trypanosomiasis), Diabetic Complications, Encephalomyelitis, Focal Segmental Glomerulosclerosis (FSGS), Glomerulonephritis, Huntington Disease, Idiopathic Pulmonary Fibrosis, Idiopathic Pulmonary Hypertension, Ischemia Reperfusion Injury, Ischemic Stroke, Medulloblastoma, Metastatic Breast Cancer, Metastatic Melanoma, Neuroblastoma, Neurodegenerative Diseases, Non Alcoholic Fatty Liver Disease (NAFLD), Non-Hodgkin Lymphoma, Non-Small Cell Lung Cancer, Osteoarthritis, Osteoporosis, Ovarian Cancer, Plaque Psoriasis (Psoriasis Vulgaris), Polycystic Kidney Disease, Post-Myocardial Infarction, Primary Progressive Multiple Sclerosis (PPMS), Prostate Cancer, Proteinuria, Pulmonary Hypertension, Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome), Radiodermatitis, Relapsing Remitting Multiple Sclerosis (RRMS), Retinopathy, Subarachnoid Hemorrhage and Ulcerative Colitis.

Furthermore, this report also reviews key players involved in Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The report provides a snapshot of the global therapeutic landscape for Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2)
  • The report reviews Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) targeted therapeutics
Reasons for Purchase:
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Arbor Pharmaceuticals LLC
  • Bayer AG
  • BioApex sro
  • Biogen Inc
  • Daiichi Sankyo Co Ltd
  • Evgen Pharma Plc
  • MORE
Introduction

Report Coverage

Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) - Overview

Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) - Companies Involved in Therapeutics Development

Arbor Pharmaceuticals LLC

Bayer AG

BioApex sro

Biogen Inc

C4X Discovery Holdings PLC

Catabasis Pharmaceuticals Inc

Daiichi Sankyo Co Ltd

Evgen Pharma Plc

Ixchel Pharma LLC

Jiangsu Hengrui Medicine Co Ltd

Mochida Pharmaceutical Co Ltd

Reata Pharmaceuticals Inc

Rigel Pharmaceuticals Inc

vTv Therapeutics Inc

Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) - Drug Profiles

(alpha lipoic acid + losartan potassium) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BA-1521 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

bardoxolone methyl - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CAT-4001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DH-404 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

dimethyl fumarate DR - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IXC-103 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LGM-2605 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LH-503 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LH-526 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MG-132 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MIND-4 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

monosodium luminol - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

nifurtimox - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

omaveloxolone - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

R-970 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RS-9 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RTI-79 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SFX-01 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SFX-02 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SFX-03 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Activate NF-E2 Related Factor 2 for Central Nervous System, Metabolic Disorders, Cardiovascular and Ophthalmology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Activate Nrf2 for Inflammation - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Activate Nrf2 for Inflammation - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Target NRF2 and BACH1 for Parkinson’s Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules 2 to Activate Nrf2 for Oncology and Inflammation - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Activate NFE2L2 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Activate NRF-2 for COPD - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Activate Nrf2 for Oncology and Inflammation - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Target GSK3B and Nrf2 for Alzheimer's Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SUL-121 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TBE-31 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tepilamide fumarate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TFM-735 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VCB-101 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VCB-102 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VEDA-1209 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) - Dormant Products

Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) - Discontinued Products

Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) - Product Development Milestones

Featured News & Press Releases

Jun 04, 2018: Reata Announces That Kyowa Hakko Kirin Initiated AYAME, a Phase 3 Trial of Bardoxolone Methyl for the Treatment of Diabetic Kidney Disease

May 31, 2018: Kyowa Hakko Kirin Initiated Phase 3 Clinical Study of Bardoxolone Methyl (RTA 402) for Diabetic Kidney Disease

May 31, 2018: Reata Announces Orphan Drug Designation From the European Commission for Bardoxolone Methyl for the Treatment of Alport Syndrome

May 25, 2018: Bardoxolone Methyl Improved Kidney Function in Patients With Autosomal Dominant Polycystic Kidney Disease and IgA Nephropathy in the Ongoing Phase 2 Phoenix Study

May 02, 2018: Evgen Pharma: Grant of further European patent

Apr 24, 2018: Evgen Pharma Announces Presentation at World Orphan Drug Congress USA

Apr 24, 2018: Reata Announces New Preclinical Data Demonstrating the Potential of Omaveloxolone in the Treatment of Friedreich’s Ataxia and Other Severe Neurological Diseases

Apr 11, 2018: Reata Provides Update on the Phase 2 Portion of the CARDINAL Study of Bardoxolone Methyl in Patients with Alport Syndrome

Mar 29, 2018: Reata Announces That Kyowa Hakko Kirin Received SAKIGAKE Priority Review Designation for Bardoxolone Methyl in Japan

Mar 28, 2018: Bardoxolone Methyl (RTA 402) Designated for the Treatment of Diabetic Kidney Disease under the Priority Review and Designation System by the Ministry of Health, Labour and Welfare

Mar 22, 2018: Reata Announces Positive Top-Line Data for Treatment of PH-ILD With Bardoxolone Methyl From the Phase 2 Lariat Trial

Mar 06, 2018: V ClinBio Partners with Camargo for Strategic 505(b)(2) Development of Multiple Sclerosis Drug Candidate CLX-106

Mar 05, 2018: Evgen Pharma: Update on novel sulforaphane analogues

Mar 01, 2018: Reata Announces Top-Line Data from the Dose-Escalation Cohorts of the Phase 2 Motor Study of Omaveloxolone in Patients With Mitochondrial Myopathies

Feb 27, 2018: Reata Provides Program Update on Phase 2 Rare Renal Clinical Trials

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development by Stage of Development, H1 2018

Number of Products under Development by Therapy Areas, H1 2018

Number of Products under Development by Indications, H1 2018

Number of Products under Development by Indications, H1 2018 (Contd..1), H1 2018

Number of Products under Development by Indications, H1 2018 (Contd..2), H1 2018

Number of Products under Development by Indications, H1 2018 (Contd..3), H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Companies, H1 2018 (Contd..1)

Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Products under Development by Companies, H1 2018 (Contd..2), H1 2018

Products under Development by Companies, H1 2018 (Contd..3), H1 2018

Number of Products under Investigation by Universities/Institutes, H1 2018

Products under Investigation by Universities/Institutes, H1 2018

Products under Investigation by Universities/Institutes, H1 2018 (Contd..1), H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Pipeline by Arbor Pharmaceuticals LLC, H1 2018

Pipeline by Bayer AG, H1 2018

Pipeline by BioApex sro, H1 2018

Pipeline by Biogen Inc, H1 2018

Pipeline by C4X Discovery Holdings PLC, H1 2018

Pipeline by Catabasis Pharmaceuticals Inc, H1 2018

Pipeline by Daiichi Sankyo Co Ltd, H1 2018

Pipeline by Evgen Pharma Plc, H1 2018

Pipeline by Ixchel Pharma LLC, H1 2018

Pipeline by Jiangsu Hengrui Medicine Co Ltd, H1 2018

Pipeline by Mochida Pharmaceutical Co Ltd, H1 2018

Pipeline by Reata Pharmaceuticals Inc, H1 2018

Pipeline by Rigel Pharmaceuticals Inc, H1 2018

Pipeline by vTv Therapeutics Inc, H1 2018

Dormant Products, H1 2018

Dormant Products, H1 2018 (Contd..1), H1 2018

Dormant Products, H1 2018 (Contd..2), H1 2018

Discontinued Products, H1 2018

List of Figures

Number of Products under Development by Stage of Development, H1 2018

Number of Products under Development by Therapy Areas, H1 2018

Number of Products under Development by Top 10 Indications, H1 2018

Number of Products by Mechanism of Actions, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Arbor Pharmaceuticals LLC
  • Bayer AG
  • BioApex sro
  • Biogen Inc
  • C4X Discovery Holdings PLC
  • Catabasis Pharmaceuticals Inc
  • Daiichi Sankyo Co Ltd
  • Evgen Pharma Plc
  • Ixchel Pharma LLC
  • Jiangsu Hengrui Medicine Co Ltd
  • Mochida Pharmaceutical Co Ltd
  • Reata Pharmaceuticals Inc
  • Rigel Pharmaceuticals Inc
  • vTv Therapeutics Inc
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll